Barclays analyst Gena Wang maintains $PTC Therapeutics (PTCT.US)$ with a hold rating, and adjusts the target price from $45 to $56.
According to TipRanks data, the analyst has a success rate of 41.2% and a total average return of 6.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $PTC Therapeutics (PTCT.US)$'s main analysts recently are as follows:
Recently, PTC Therapeutics entered into a global licensing and collaboration agreement with a major industry player for its Huntington's Disease program, PTC518. Under this agreement, substantial financial benefits are anticipated including a considerable upfront payment and potential for further financial gains linked to milestones in development, regulatory achievements, and sales. This deal is viewed favorably as it not only provides significant capital but also allows PTC to maintain major economic interests and broadens the potential for substantial success. Adding to this, PTC is positioned strongly into 2025, expected to emerge as a diversified company focused on rare diseases with several critical catalysts anticipated over the coming year.
The firm has expressed encouragement following the announcement that the company has entered into an exclusive strategic license agreement with a major pharmaceutical company for the global development of a key drug in Huntington's disease. This agreement is seen as a positive move that alleviates short-term cash concerns. Additionally, the company is actively seeking regulatory alignment on an accelerated approval pathway after a favorable phase 2 update and is keen on gaining further clarity on future development plans, which are considered to still require risk mitigation.
The agreement with Novartis is viewed favorably, characterized by significant upfront payment and developmental milestones. This deal enhances the financial stability of PTC and affirms the value of its platform, although it also shifts developmental risk.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
